AUS
NZ
UK
CA
USA
IND
Cortical Dynamics, incorporated in 2004, is an Australian medical device technology developer with a breakthrough system for reliable monitoring of the brain response towards anaesthetic agents- Brain Anaesthesia Response Monitor (or BARM).
For more details on Cortical Dynamics, please visit: www.corticaldynamics.com
Cortical is engaged in the commercialisation of the BARM, which is an intellectual property developed by Professor David Liley. Professor Liley currently holds honorary appointments in the Department of Medicine at the University of Melbourne, Clinical Neurosciences at St Vincent’s Hospital Melbourne and the Centre for Human Psychopharmacology at Swinburne University of Technology.
Cortical’s Brain Monitoring System known as “BARM” uses a fundamentally superior algorithm to current monitors to analyse an individual’s brain waves through EEG, via a single patient use sensor and provides two indices:
- CCS: Measure of hypnosis (unconsciousness)
- CI: measure of analgesia (pain)
- BARM calibrates anaesthetic monitoring to the individual patient rather than using a statistical average (Cortical’s major competitors BIS & Entropy)
- It also monitors a wider range of drugs than does BIS and Entropy.
As the paradigm-busting technology is supportive for providing the optimal anaesthesia level for the patients, it enables the potential of reducing the operating cost of the healthcare sector by reducing the patients’ post-operative recovery time.
The Competitive Edge:
Further significant advantages of the BARM system is its detection of anaesthetic agents such as Ketamine, Nitrous Oxide and Opiods, where current global market leaders of BIS(Medtronic) and E-Entropy (GE) do not detect these anaesthetic agents.
The advanced BARM technology provides the company with a global advantage.
Lens Over the Business Opportunity:
Cortical Dynamics has secured Therapeutic Goods Administration (or TGA) approval in Australia and the CE mark in Europe in early 2016. Now, the company is currently targeting the UK, European, Asia-Pacific, and South American markets.
The global brain monitoring market generated around $3,850 million in 2017, and the current trend of high demand for EEG devices in the global healthcare sector represents a reliable business opportunity.
There are around 312 million major surgery cases annually in the global market, which includes anaesthesia. The primary markets targeted by the company such as Europe, Australia, the United States conduct a substantial number of major surgeries annually, including anaesthesia.
In Western Europe alone, there are about 29 million major surgery cases annually, which includes anaesthesia, while there are approximately 50 million surgeries conducted annually with anaesthesia in the United States.
Current Activities of the Company:
The company has already entered early-stage sales and marketing activities for BARM systems in Australia and signed distributorship for the product in the initially targeted markets of South Korea and Europe.
The company further intends to develop sales of the BARM system in Australia and New Zealand along with the key market segments in Europe, the UK, and in the United States.
In a nutshell, Cortical is engaged in the commercialisation of the advance medical technology- BARM system, which tracks the brain’s hypnotic and analgesic response, when a patient is administered with either TIVA or anaesthetic inhaled gases such as Sevoflurane, Desflurane or Isoflurane.
The paradigm-bursting technology of the company holds the potential of reducing the high operating cost issue of the healthcare industry, and the global market of anaesthesia-based major operations is vast with no current reliable measure to detect the hypnotic level.
Please click here for the offer document.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is sponsored but NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. We are neither licensed nor qualified to provide investment advice through this platform.
